Success Metrics

Active Trials

1(25%)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Not yet recruiting3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

not_yet_recruiting375%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379

not_yet_recruitingphase_2

Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

NCT07374250

not_yet_recruitingphase_2

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

NCT07162714

not_yet_recruitingphase_2

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

NCT07095803

Clinical Trials (4)

Showing 4 of 4 trials

NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting

NCT07374250Phase 2

Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

Not Yet Recruiting

NCT07162714Phase 2

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Not Yet Recruiting

NCT07095803Phase 2

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4